Compare Garmin Ltd. (GRMN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Novo Nordisk A/S — how do they compare? Garmin Ltd. trades at $268.36 (market cap $51.77B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.2× Garmin Ltd.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Novo Nordisk A/S for 116 Days on average.
| GRMN | NVO | |
|---|---|---|
Market Cap | $51.77B | $165.31B |
Volume | 961,398 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $313.16 | $63.98 |
52-Week Low | $187.10 | $35.29 |
Typical Hold Time | 83 Days | 116 Days |
Enterprise Value | $49.28B | $179.56B |
Dividend Yield | 1.56% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.44, down 2.8% on the day, amid a bearish technical signal. The stock has demonstrated strong fundamental performance with revenue growing from $4.9B in 2022 to $7.25B in 2025 and net income reaching $1.66B. Recent earnings beats and consistent dividend payments highlight operational strength, while analyst consensus targets $320.25, suggesting potential upside from current levels.
The outlook remains positive given robust profitability and product innovation, but risks include competitive pressures and market volatility. Institutional ownership trends and a Zacks Strong Buy upgrade reflect confidence, yet the stock faces headwinds from broader economic conditions and execution challenges in maintaining growth momentum.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
